RISEDRONATE SODIUM

Post-LOE

risedronate sodium

Aurobindo Pharma

ANDAORALTABLET

Approved

Nov 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

RISEDRONATE SODIUM (risedronate sodium) by Aurobindo Pharma is agent. Approved for paget’s disease of bone in men, women. First approved in 2015.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone…

Indications (2)

Paget’s disease of bone in men women

Worked on RISEDRONATE SODIUM at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (2)

NCT00460733Phase 4Completed

SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.

Started Mar 2007

141 enrolled

Colles' Fracture

NCT00453492Phase 4Completed

Risedronate Sodium in Post Menopausal Osteoporosis

Started Jan 2004

246 enrolled

Osteoporosis, Postmenopausal